StemGen is a clinical stage biotech company
developing innovative differentiation biotherapies for cancer.
The complete website will be online soon
hrBMP4 gets the Orphan Drug designation by EMA for the treatment of glioma. Year 2014.
StemGen S.p.A is an Italian biotechnology company created in 2006 and engaged in the research and development of innovative oncological therapies, for improving the lives of people with gliomas and glioblastomas. The Company, which was built upon the knowledge and expertise of a world-class research team led by renowned neuroscientist Prof. Angelo Vescovi, is a drug discovery and development company.
Rare tumors
Glioblastoma Multiforme is the most common and aggressive malignant primary brain tumour, considered incurable.
Current standard of care is of limited benefit and prognosis is poor.
Our solution: differentiation therapy
A therapy that turns cancer stem cells into "normal" mature brain cells.
Copyright 2019 © STEMGEN S.p.A. | Piazza della Scienza, 2 - 20126 Milano (IT) | PIVA 05041640961